Welcome to Molecular Oncology Tumor Boards

The Molecular Oncology Tumor Boards are a series of bi-monthly, user-driven discussions designed to help cancer care providers with the interpretation and understanding of tumor molecular profiling tests and studies. Moderated by an expert pathologist and medical oncologist, each case will be updated with new information over a 2-week period as user comments are added. Sign in with your ASCO username and password to participate. After 2 weeks, the discussion will be locked to further commentary and users will be able to claim CME credit for their participation. Visit ASCO University to learn more. 

To participate in discussions on other oncology-related topics, visit ASCO’s member community on myConnection. Connect with colleagues, build your professional network, exchange ideas, collaborate, and more

LOGIN TO START A DISCUSSION
Molecular Oncology Tumor Board
ASCO University
May 10, 2017 8:23 AM
Read more to answer the following questions: 1) Is the location and morphology of this tumor significant clinically? 2) Prior to NGS what additional testing could have been performed? 3) Is one test for hereditary colon cancer better than the other? 4) What is the role of genetic counseling for...
Molecular Oncology Tumor Board
ASCO University
Apr 12, 2017 9:01 AM
Read more to answer the following questions: 1) Would you recommend clinical genetics consultation for BRCA testing? Would an expanded panel be beneficial? 2) What would be the next step in this patient’s management? 3) Is there a value in performing biopsy of liver lesion before starting any...
Molecular Oncology Tumor Board
ASCO University
Mar 15, 2017 9:47 AM
Read more to answer the following questions:
1. Who should get routine molecular testing at the time of diagnosis of NSCLC and what genes should be included in the molecular panel?
2. What is the proper timing of testing and sequencing of available therapies?
3. What treatment options are available...
Molecular Oncology Tumor Board
ASCO University
Feb 15, 2017 8:30 AM
Read more to answer the following questions:
1.    Recognize the diagnosis of CML and importance of bone marrow biopsy at presentation.
2.    Apply considerations when choosing initial therapy.
3.    Recognize when to switch therapy when response is suboptimal.
4.    Identify how to treat...
Molecular Oncology Tumor Board
ASCO University
Jan 11, 2017 2:00 PM
Read more to answer the following questions: 1) Which tests are the most appropriate in identifying a BRAF codon 600 mutation for potential FDA-targeted treatment? 2) What is the significance of the CDKN2A mutation? 3) If systemic therapy is selected, would you be more inclined to offer targeted...

Pages


Advertisement